摘要
许多强迫症患者部分或根本不对标准药物和认知行为治疗方法做出反应,需要进行替代治疗。我们回顾了在一些强迫症患者中支持使用兴奋剂,高剂量咖啡因,阿片类药物,美金刚,恩丹西酮,氯胺酮和经颅磁刺激的初步证据。虽然受到小样本或适度样本量,开放标签研究设计和短暂随访期的限制,但研究表明,这些策略中的每一种都可以帮助一些对一线治疗反应不足的患者。 OCD患者的现有数据和未满足的需求证明了研究注意力,以进一步测试这些治疗的安全性和有效性。以前未经检验的药物也值得关注,特别是最近的研究表明OCD病理生理学的新可能贡献者。同样,应该调查CBT之外的心理治疗干预,并且应该仔细测试OCD中的初步证据治疗,包括接受承诺治疗,危险想法减少治疗和技术支持的干预,如计算机化CBT和虚拟现实暴露治疗。
关键词: 强迫症,d-苯丙胺,咖啡因,兴奋剂,美金刚,昂丹司琼,经颅磁刺激.
Current Medicinal Chemistry
Title:Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research
Volume: 25 Issue: 41
关键词: 强迫症,d-苯丙胺,咖啡因,兴奋剂,美金刚,昂丹司琼,经颅磁刺激.
摘要: Many patients with OCD respond partially or not at all to standard medications and cognitive behavioral therapy approaches, making alternate treatments necessary. We review the preliminary evidence that exists in support of the use of stimulants, high-dose caffeine, opiates, memantine, ondansetron, ketamine, and transcranial magnetic stimulation in some patients with OCD. Although limited by small or modest sample sizes, open-label study designs, and brief follow-up periods, studies suggest that each of these strategies can help some patients who have inadequately responded to first-line treatments. The existing data and the unmet needs of OCD patients justify research attention to further test these treatments’ safety and efficacy. Previously untested drugs also deserve attention, especially as recent research has suggested new possible contributors to OCD pathophysiology. Similarly, psychotherapeutic interventions beyond CBT should be investigated, and treatments with preliminary evidence in OCD, including Acceptance Commitment Therapy, Danger Ideation Reduction Therapy, and technology-enabled interventions like computerized CBT and Virtual Reality Exposure Therapy, should be carefully tested.
Export Options
About this article
Cite this article as:
Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research, Current Medicinal Chemistry 2018; 25 (41) . https://dx.doi.org/10.2174/0929867324666170526120916
DOI https://dx.doi.org/10.2174/0929867324666170526120916 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements